Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: Potential biomarker significance

Pathology

Volumn 46, Issue 6, 2014, Pages 518-522

  Rajandram, R ^a,b   Yap, N Y ^a   Pailoor, J ^a,c   Razack, A H A ^a,c   Ng, K L ^a,b,c   Ong, T A ^a,c   Morais, C ^b   Gobe, G C ^b,d  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^d TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Kidney cancer; Renal cell carcinoma; TRAF; Tumour necrosis factor receptor associated factor

Indexed keywords

TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADULT; AGED; AUSTRALIA; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALAYSIA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AUSTRALIA; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MALAYSIA; MALE; MIDDLE AGED; PROGNOSIS; TNF RECEPTOR-ASSOCIATED FACTOR 1;

EID: 84961291309     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000145     Document Type: Article

References (47)

1. Eble JN, Sauter G, Epstein JI, et al. World Health Organization Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004; 12-31.
2. Lopez-Beltran A, Scarpelli M, Montironi R, et al. WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
3. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med 2005; 353: 2477-90.
4. Axelson H, Johansson ME. Renal stem cells and their implications for kidney cancer. Semin Cancer Biol 2013; 23: 56-61.
5. Sfoungaristos S, Giannitsas K, Perimenis P. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma. Expert Opin Pharmacother 2011; 12: 533-47.
6. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-30.
7. Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRFA3 and activates NF-kappaB, elk1, c-Jun Nterminal kinase, and p53 mitogen-activated kinase. J Immunol 2000; 165: 1322-30.
8. Chen H, Li M, Campbell RA, et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006; 25: 6520-7.
9. Izban KF, Alkan S, Singleton TP, et al. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21(WAF1), p27(KIP1), and p53 in mantle cell lymphoma. Arch Pathol Lab Med 2000; 124: 1457-62.
10. Zapata JM, Llobet D, Krajewska M, et al. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 2009; 113: 4595-603.
11. Zhang B, Wang Z, Li T, et al. NF-kappaB2 mutation targets TRAF-1 to induce lymphomagenesis. Blood 2007; 110: 743-51.
12. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family - Scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001; 13: 389-400.
13. Lavorgna A, De Filippi R, Formisano S, et al. TNF receptor-associated factor 1 is a positive regulator of the NF-kappaB alternative pathway. Mol Immunol 2009; 46: 3278-82.
14. Chung JY, Park YC, Ye H, et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115: 679-88.
15. Sabbagh L, Srokowski CC, Pulle G, et al. A critical role for TNF receptorassociated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci USA 2006; 103: 18703-8.
16. Rajandram R, Pat BK, Li J, et al. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology 2009; 14: 205-12.
17. Rajandram R, Bennett NC, Wang Z, et al. Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy. Pathology 2012; 44: 453-9.
18. Santos N, Wenger JB, Havre P, et al. Combination therapy for renal cell cancer, what are possible options? Oncology 2011; 81: 220-9.
19. Porta C, Sabbatini R, Procopio G, et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma, state-of-the-science. Exp Rev Anticancer Ther 2012; 12: 1571-7.
20. Wang H, Wang H, Zhang W, et al. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol 2002; 12: 104-11.
21. Lopez JI, Guarch R, Larrinaga G, et al. Cell heterogeneity in clear cell renal cell carcinoma. APMIS 2013. Mar 20: (Epub ahead of print).
22. Staniszewski W. Image analysis using the Aperio ScanScope. Folia Histochem Cytobil 2009; 47: 699-701.
23. Hughes J, Gobe G. Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology 2007; 12: 452-8.
24. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20: 6482-91.
25. Irmler M, Steiner V, Ruegg C, et al. Caspase-induced inactivation of the anti-apoptotic TRAF-1 during Fas ligand-mediated apoptosis. FEBS Lett 2000; 468: 129-33.
26. Oyoshi MK, Bryce P, Goya S, et al. TNF receptor-associated factor 1 expressed in resident lung cells is required for the development of allergic lung inflammation. J Immunol 2008; 180: 1878-85.
27. Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF-1 is a negative regulator of TNF signaling: Enhanced TNF signaling in TRAF-1-deficient mice. Immunity 2001; 15: 647-57.
28. Leo E, Deveraux QL, Buchholtz C, et al. TRAF-1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis. J Biol Chem 2001; 276: 8087-93.
29. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16 (Suppl 2): 14-22.
30. Gobe G, Rubin M, Williams G, et al. Apoptosis and expression of Bcl-2, Bcl-X-L, and Bax in renal cell carcinomas. Cancer Invest 2002; 20: 324-32.
31. Ramp U, Caliskan E, Mahotka C, et al. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer 2003; 88: 1800-7.
32. Rajandram R, Pat BK, Li J, et al. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology 2009; 14: 205-12.
33. Davidson K, Percy C, Rennick AJ, et al. Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. Nephron Exp Nephrol 2005; 99: E112-20.
34. Wu XX, Kakehi Y, Mizutani Y, et al. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001; 19: 19-24.
35. Inoue J, Ishida T, Tsukamoto N, et al. Tumor necrosis factor receptorassociated factor (TRAF) family: adaptor proteins that mediate cytokine signalling. Exp Cell Res 2000; 254: 14-24.
36. Henkler F, Baumann B, Fotin-Mleczek M, et al. Caspase-mediated cleavage converts the tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 from a selective modulator of TNF receptor signaling to a general inhibitor of NF-kappaB activation. J Biol Chem 2003; 278: 29216-30.
37. Arron JR, Walsh MC, Choi Y. TRAF-mediated TNFR-family signaling. Curr Protoc Immunol 2002. NOV: Chapter 11, Unit 11.9D.
38. Arron JR, Pewzner-Jung Y, Walsh MC, et al. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med 2002; 196: 923-34.
39. Dunn IF, Geha RS, Tsitsikov EN. Structure of the murine TRAF1 gene. Mol Immunol 1999; 36: 611-7.
40. Xie P, Hostager BS, Munroe ME, et al. Cooperation between TNF receptorassociated factors 1 and 2 in CD40 signaling. J Immunol 2006; 176: 5388-400.
41. Jensen HK, Donskov F, Marcussen N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-17.
42. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2010; 109: 1500-6.
43. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-9.
44. Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma. Br J Cancer 2002; 86: 1396-400.
45. Chuang MJ, Sun KH, Tang SJ, et al. Tumor-derived tumor necrosis factoralpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008; 99: 905-13.
46. Schwenzer R, Siemienski K, Liptay S, et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 1999; 274: 19368-74.
47. Zapata JM, Lefebvre S, Reed JC. Targeting TRAFs for therapeutic intervention. TNF Receptor Associated Factors (TRAFs). Adv Exp Med Biol 2007; 597: 188-201.